(Fargo, ND) -- Some big moves for one local company continuing to try and innovate in the field of bio tech.
Danaher Corp. announced Thursday that it has purchased Aldevron, the Fargo-based company that has been a major hub for making a key ingredient for COVID-19 vaccines.
In a released announcement, Danaher announced that it has entered into a "definitive agreement" to purchase privately held Aldevron, which was founded in 1998 on the campus of NDSU by Michael Chambers and John Ballantyne.
The company, which has a growing campus in south Fargo, employs about 600 people and manufactures high-quality plasmid DNA, mRNA and proteins for biotechnology and biopharmaceutical customers engaged in research, clinical and commercial applications.
"We are thrilled to have Aldevron join Danaher's Life Sciences segment," Rainer M. Blair, Danaher's president and chief executive officer, said in a statement. "For nearly 25 years, Aldevron has made tremendous contributions to the advancement of cell, gene and other novel therapies and vaccines."
The sale was for $9.6 billion.
